18
total announcements
540359.BO · 15 min delayed
Parmax Pharma Ltd
Parmax Pharma Ltd has allotted 31,37,586 equity shares and 21,45,145 convertible warrants on a preferential basis to non-promoter category investors at an issue price of ₹36.50 per share and ₹36.50 per warrant respectively.
Parmax Pharma Ltd
Parmax Pharma Ltd has informed the BSE about the reclassification of promoters under Regulation 31A of SEBI (LODR) Regulations, 2015. The company has received undertakings from the erstwhile promoters seeking reclassification confirming compliance with the conditions as specified under clauses (b) and (c)(ii)&(iii) of sub-regulation (3) of Regulation 31A of SEBI LODR Regulations.
Parmax Pharma Ltd
Parmax Pharma Ltd has submitted a copy of Post Offer Advertisement to BSE as per Regulation 18(12) of the Securities and Exchange Board of India (SAST) Regulations, 2011, in relation to the open offer for acquisition of up to 23,46,250 equity shares of the company.
Parmax Pharma Ltd
Parmax Pharma Ltd has received in-principle approval from BSE Limited under Regulation 28(1) of the SEBI LODR Regulations for the issuance of equity shares and warrants on a preferential basis.
Parmax Pharma Ltd
Parmax Pharma Ltd has announced the newspaper publication of the extract of financial results for the quarter ended June 30, 2026, as per Regulation 30 of the SEBI (LODR) Regulations, 2015. The company has also announced the notice of its 20th Annual General Meeting (AGM) to be held on September 8, 2026, through video conferencing.
Parmax Pharma Ltd
Parmax Pharma Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Alkesh Mahasukhlal Gopani & Others, indicating a potential change in shareholding.
Parmax Pharma Ltd
Parmax Pharma Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, stating that Dhiren Chandulal Shah and Sunil Chinubhai Shah have acquired 11,52,450 equity shares of the company on August 13, 2026, pursuant to a Share Purchase Agreement dated June 08, 2026. This acquisition has increased their shareholding in the company to 58.01%.
Parmax Pharma Ltd
Parmax Pharma Ltd announced the appointment of Mr. Dhiren Shah, Mr. Sunil Shah as Additional Directors and recommendation of Ms. Anjana Shah, Ashish Shah as Independent Directors. The company also released unaudited financial results for the quarter ended June 30, 2026.
Parmax Pharma Ltd
Parmax Pharma Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, reporting a net profit of Rs. 21,994.93 lakhs. The company's revenue from operations was Rs. 82,209.52 lakhs, and its expenses totaled Rs. 81,005.89 lakhs. The board of directors has also approved the appointment of four new directors, including Mr. Dhiren Chandulal Shah as the Chairman of the company.
Parmax Pharma Ltd
Parmax Pharma Ltd announced its unaudited financial results for the quarter ended June 30, 2026, with a net profit of Rs. 21994.93 and a loss of Rs. 5843.31. The company also announced the appointment of new directors and the resignation of an existing director. The results were reviewed by the Audit Committee and approved by the Board of Directors.
Parmax Pharma Ltd
Parmax Pharma Ltd has received a disclosure under Regulation 18(6) of SEBI (SAST) Regulations, 2011, regarding the acquisition of 11,52,450 equity shares by Dhiren Chandulal Shah and Sunil Chinubhai Shah, and other persons, pursuant to a Share Purchase Agreement dated June 08, 2026.
Parmax Pharma Ltd
Parmax Pharma Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 14/08/2026 to consider and approve quarterly financial results for the quarter ended June 30, 2026.
Parmax Pharma Ltd
Parmax Pharma Ltd has submitted a copy of newspaper publication of Offer Opening Pre-Offer Advertisement to the Public Shareholders of Parmax Pharma Ltd as part of the open offer for acquisition of up to 23,46,250 equity shares, representing 26% of the expanded voting share capital, by Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with other persons acting in concert.
Parmax Pharma Ltd
Parmax Pharma Ltd has received a copy of the newspaper publication of the Committee of Independent Directors' (IDC) recommendations to public shareholders regarding an open offer for the acquisition of up to 23,46,250 equity shares, representing 26% of the company's expanded voting share capital, by Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with other persons acting in concert.
Parmax Pharma Ltd
Parmax Pharma Ltd has received a letter of offer from Fedex Securities Pvt Ltd, the manager to the offer, for the acquisition of up to 23,46,250 equity shares, representing 26% of the expanded voting capital, by Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with 10 persons acting in concert, at a price of ₹42.80 per equity share.
Parmax Pharma Ltd
Parmax Pharma Ltd has issued a corrigendum to its Extraordinary General Meeting (EGM) notice dated June 8, 2026, which was called for a preferential issue of equity shares and convertible warrants. The corrigendum corrects the proposed status of Ms. Sheetal Hiren Doshi in the warrant allottees table from 'Promoter*' to 'Promoter Group*'. Additionally, a hyperlink for the Practicing Company Secretary’s Certificate in the explanatory statement has been rectified. All other items of the EGM Notice remain unchanged, with the EGM scheduled for July 2, 2026.
Parmax Pharma Ltd
A non-promoter shareholder, Pradeep Ramniklal Gosalia, disclosed the disposal of 3,00,000 equity shares of Parmax Pharma Ltd through an off-market transfer on June 18, 2026. This transaction reduced his holding from 8.09% (3,02,714 shares) to 0.07% (2,714 shares). This is a compliance filing under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, reporting a significant reduction in a substantial non-promoter's stake.
Parmax Pharma Ltd
Fedex Securities Pvt Ltd, Manager to the Offer, has submitted a Draft Letter of Offer for an open offer to acquire up to 2,346,250 equity shares, representing 26.00% of Parmax Pharma Ltd's expanded voting capital, from its public shareholders. The offer is made by Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with ten Persons Acting in Concert (PACs), at a price of ₹42.80 per equity share, in compliance with SEBI (SAST) Regulations, 2011.